ARTELO BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
ARTELO BIOSCIENCES, INC. (ARTL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $878.02 thousand for the 12-month period ending 2019-08-31, per its 10-K/A filed 2019-12-18.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2019-12-18
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2019-08-31 was $341.33K.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2019-05-31 was $0.00.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2019 was $878.02K, a 63.60% increase from fiscal 2018.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2018 was $536.69K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2019-08-31 | $341.33K derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-12-18 | $341.33K derived: sum of 2 quarters · filed 2019-12-18 | $878.02K 10-K/A · filed 2019-12-18 | |
| 2019-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-07-15 | $536.69K 10-Q · filed 2019-07-15 | ||
| 2019-02-28 | $536.69K 10-Q · filed 2019-04-15 | |||
| 2018-08-31 | $536.69K 10-K/A · filed 2019-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |